The city of Albuquerque, New Mexico, currently has 25 active clinical trials seeking participants for Breast Cancer research studies.
Monitoring Response to Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer Using High-speed MR Spectroscopic Imaging
Recruiting
The study will assess whether changes in total choline concentration \[tCho\] during neoadjuvant chemotherapy (NAC) are predictive of pathologic complete response (pCR) in patients with HER2 negative breast cancer (HNBC) appropriate for NAC, and compare these findings with dynamic contrast enhanced magnetic resonance imaging (DCE-MRI). The objective is to assess the predictive value of changes in the concentration and spatial extent of tCho within the tumor during NAC.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/09/2024
Locations: University of New Mexico Comprehensive Cancer Center, Albuquerque, New Mexico
Conditions: HER2 Negative Breast Cancer